• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过组织蛋白酶 S 介导的泛素降解来调节 BRCA1 蛋白稳定性。

Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation.

机构信息

Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, 120-750, Korea.

Functional Morphometry II, Institute Pasteur Korea, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400, Korea.

出版信息

Cell Death Differ. 2019 May;26(5):812-825. doi: 10.1038/s41418-018-0153-0. Epub 2018 Jul 13.

DOI:10.1038/s41418-018-0153-0
PMID:30006610
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6461859/
Abstract

Cathepsin S (CTSS) is a cysteine protease that is thought to play a role in many physiological and pathological processes including tumor growth, angiogenesis, and metastasis; it has been identified as a radiation response gene. Here, we examined the role of CTSS in regulating the DNA damage response in breast cancer cells. Activating CTSS (producing the cleavage form of the protein) by radiation induced proteolytic degradation of BRCA1, which ultimately suppressed DNA double-strand break repair activity. Depletion of CTSS by RNAi or expression of a mutant type of CTSS enhanced the protein stability of BRCA1 by inhibiting its ubiquitination. CTSS interacted with the BRCT domain of BRCA1 and facilitated ubiquitin-mediated proteolytic degradation of BRCA1, which was tightly associated with decreased BRCA1-mediated DNA repair activity. Treatment with a pharmacological CTSS inhibitor inhibited proteolytic degradation of BRCA1 and restored BRCA1 function. Depletion of CTSS by shRNA delayed tumor growth in a xenograft mouse model, only in the presence of functional BRCA1. Spontaneously uced rat mammary tumors and human breast cancer tissues with high levels of CTSS expression showed low BRCA1 expression. From these data, we suggest that CTSS inhibition is a good strategy for functional restoration of BRCA1 in breast cancers with reduced BRCA1 protein stability.

摘要

组织蛋白酶 S(CTSS)是一种半胱氨酸蛋白酶,被认为在许多生理和病理过程中发挥作用,包括肿瘤生长、血管生成和转移;它已被确定为辐射反应基因。在这里,我们研究了 CTSS 在调节乳腺癌细胞中 DNA 损伤反应中的作用。辐射通过激活 CTSS(产生蛋白质的裂解形式)诱导 BRCA1 的蛋白水解降解,最终抑制 DNA 双链断裂修复活性。通过 RNAi 耗竭 CTSS 或表达突变型 CTSS 通过抑制其泛素化来增强 BRCA1 的蛋白稳定性。CTSS 与 BRCA1 的 BRCT 结构域相互作用,并促进 BRCA1 的泛素介导的蛋白水解降解,这与 BRCA1 介导的 DNA 修复活性降低密切相关。用药理学 CTSS 抑制剂抑制 BRCA1 的蛋白水解降解并恢复 BRCA1 功能。用 shRNA 耗竭 CTSS 仅在存在功能性 BRCA1 的情况下延迟异种移植小鼠模型中的肿瘤生长。自发诱导的大鼠乳腺肿瘤和高 CTSS 表达水平的人类乳腺癌组织显示 BRCA1 表达水平降低。从这些数据中,我们认为 CTSS 抑制是恢复具有降低 BRCA1 蛋白稳定性的乳腺癌中 BRCA1 功能的一种很好的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/8fc20c40c84d/41418_2018_153_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/f17c324d0af2/41418_2018_153_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/5501227424e7/41418_2018_153_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/ee0fd0fd47ed/41418_2018_153_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/4573792b9b30/41418_2018_153_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/a4baab8d7b58/41418_2018_153_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/4caa5c21c138/41418_2018_153_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/db194e6c62a7/41418_2018_153_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/8fc20c40c84d/41418_2018_153_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/f17c324d0af2/41418_2018_153_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/5501227424e7/41418_2018_153_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/ee0fd0fd47ed/41418_2018_153_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/4573792b9b30/41418_2018_153_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/a4baab8d7b58/41418_2018_153_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/4caa5c21c138/41418_2018_153_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/db194e6c62a7/41418_2018_153_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b6c/6461859/8fc20c40c84d/41418_2018_153_Fig8_HTML.jpg

相似文献

1
Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation.通过组织蛋白酶 S 介导的泛素降解来调节 BRCA1 蛋白稳定性。
Cell Death Differ. 2019 May;26(5):812-825. doi: 10.1038/s41418-018-0153-0. Epub 2018 Jul 13.
2
Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple-negative breast cancer cells.新型 CTSS 抑制剂通过增强三阴性乳腺癌细胞中 BRCA1 蛋白稳定性发挥放射增敏作用。
Cancer Sci. 2024 Jun;115(6):2036-2048. doi: 10.1111/cas.16174. Epub 2024 Apr 13.
3
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.BRCA1基因1185位缺失AG的肿瘤可能通过无环BRCA1的表达获得治疗抗性。
J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.
4
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.BRCA1缺陷型乳腺肿瘤对PARP抑制剂AZD2281单独使用以及与铂类药物联合使用具有高度敏感性。
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.
5
USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.USP9X 稳定 BRCA1 并赋予人类癌细胞对 DNA 损伤剂的抗性。
Cancer Med. 2019 Nov;8(15):6730-6740. doi: 10.1002/cam4.2528. Epub 2019 Sep 11.
6
Up-regulation of cathepsin S expression by HSP90 and 5-HT receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer.热休克蛋白90(HSP90)和5-羟色胺受体依赖性5-羟色胺信号传导所导致的组织蛋白酶S表达上调与人类乳腺癌的三阴性相关。
Breast Cancer Res Treat. 2017 Jan;161(1):29-40. doi: 10.1007/s10549-016-4027-1. Epub 2016 Oct 27.
7
Phosphorylation of BRCA1 at serine 1387 plays a critical role in cathepsin S-mediated radiation resistance via BRCA1 degradation and BCL2 stabilization.BRCA1 丝氨酸 1387 的磷酸化在组织蛋白酶 S 介导的辐射抗性中起关键作用,其通过 BRCA1 降解和 BCL2 稳定实现。
Biochim Biophys Acta Mol Basis Dis. 2025 Jan;1871(1):167523. doi: 10.1016/j.bbadis.2024.167523. Epub 2024 Sep 25.
8
EZH2 Is Overexpressed in -like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.EZH2 在类乳腺癌中过表达,并可预测对高剂量铂类化疗的敏感性。
Clin Cancer Res. 2019 Jul 15;25(14):4351-4362. doi: 10.1158/1078-0432.CCR-18-4024. Epub 2019 Apr 29.
9
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.鼠 BRCA1 缺陷型乳腺肿瘤的蛋白质组学分析鉴定了具有潜在诊断和预后价值的人类乳腺癌 DNA 修复蛋白。
Mol Cell Proteomics. 2012 Jul;11(7):M111.013334. doi: 10.1074/mcp.M111.013334. Epub 2012 Feb 24.
10
The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.F -box 结构域依赖的 EMI1 活性调节三阴性乳腺癌对 PARPi 的敏感性。
Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.

引用本文的文献

1
Cathepsin S regulates ferroptosis sensitivity in hepatocellular carcinoma through the KEAP1-NRF2 signaling pathway.组织蛋白酶S通过KEAP1-NRF2信号通路调节肝癌中的铁死亡敏感性。
Redox Biol. 2025 Aug 6;86:103815. doi: 10.1016/j.redox.2025.103815.
2
Cathepsin B Nuclear Flux in a DNA-Guided "Antinuclear Missile" Cancer Therapy.组织蛋白酶B在DNA引导的“抗核导弹”癌症治疗中的核通量
ACS Cent Sci. 2024 Jul 15;10(8):1562-1572. doi: 10.1021/acscentsci.4c00559. eCollection 2024 Aug 28.
3
A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity.

本文引用的文献

1
Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.使用来自三阴性乳腺癌患者的福尔马林固定石蜡包埋(FFPE)肿瘤样本中BRCA1及其抑制因子的多分析物估计来鉴定BRCA1缺陷
PLoS One. 2016 Apr 14;11(4):e0153113. doi: 10.1371/journal.pone.0153113. eCollection 2016.
2
Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response.半胱氨酸组织蛋白酶蛋白酶:癌症进展和治疗反应的调节剂。
Nat Rev Cancer. 2015 Dec;15(12):712-29. doi: 10.1038/nrc4027.
3
Effects of ionizing radiation on biological molecules--mechanisms of damage and emerging methods of detection.
一种用于鉴定下调BRCA1的化合物以增强PARP抑制剂敏感性的高通量方法。
iScience. 2024 Jun 4;27(7):110180. doi: 10.1016/j.isci.2024.110180. eCollection 2024 Jul 19.
4
SOSTDC1 Nuclear Translocation Facilitates BTIC Maintenance and CHD1-Mediated HR Repair to Promote Tumor Progression and Olaparib Resistance in TNBC.SOSTDC1 核易位促进 BTIC 维持和 CHD1 介导的 HR 修复,以促进三阴性乳腺癌的肿瘤进展和奥拉帕利耐药性。
Adv Sci (Weinh). 2024 Aug;11(29):e2306860. doi: 10.1002/advs.202306860. Epub 2024 Jun 12.
5
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function.去泛素化酶USP4调节BRCA1的稳定性和功能。
NPJ Breast Cancer. 2024 May 11;10(1):35. doi: 10.1038/s41523-024-00641-7.
6
Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple-negative breast cancer cells.新型 CTSS 抑制剂通过增强三阴性乳腺癌细胞中 BRCA1 蛋白稳定性发挥放射增敏作用。
Cancer Sci. 2024 Jun;115(6):2036-2048. doi: 10.1111/cas.16174. Epub 2024 Apr 13.
7
Functional Analyses of Rare Germline Missense Variants Located within and outside Protein Domains with Known Functions.功能分析罕见种系错义变异位于已知功能的蛋白域内和域外。
Genes (Basel). 2023 Jan 19;14(2):262. doi: 10.3390/genes14020262.
8
Genome stability‑related lncRNA ZFPM2‑AS1 promotes tumor progression via miR‑3065‑5p/XRCC4 in hepatocellular carcinoma.基因组稳定性相关长非编码 RNA ZFPM2-AS1 通过 miR-3065-5p/XRCC4 促进肝细胞癌肿瘤进展。
Int J Oncol. 2023 Feb;62(2). doi: 10.3892/ijo.2022.5467. Epub 2022 Dec 16.
9
Cysteine Cathepsins in Breast Cancer: Promising Targets for Fluorescence-Guided Surgery.半胱氨酸组织蛋白酶在乳腺癌中的作用:荧光引导手术的有前途的靶点。
Mol Imaging Biol. 2023 Feb;25(1):58-73. doi: 10.1007/s11307-022-01768-4. Epub 2022 Aug 24.
10
MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma.MEOX2 介导的组织蛋白酶 S 调控促进胶质瘤细胞的增殖和迁移。
Cell Death Dis. 2022 Apr 18;13(4):360. doi: 10.1038/s41419-022-04845-2.
电离辐射对生物分子的影响——损伤机制及新兴检测方法
Antioxid Redox Signal. 2014 Jul 10;21(2):260-92. doi: 10.1089/ars.2013.5489. Epub 2014 Feb 21.
4
Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization.肿瘤细胞和肿瘤相关细胞中的组织蛋白酶 S 促进肿瘤生长和血管新生。
Int J Cancer. 2013 Nov;133(9):2102-12. doi: 10.1002/ijc.28238. Epub 2013 May 29.
5
BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation.BRCA1 靶向 G2/M 细胞周期蛋白进行泛素化和蛋白酶体降解。
Oncogene. 2013 Oct 17;32(42):5005-16. doi: 10.1038/onc.2012.522. Epub 2012 Dec 17.
6
The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation.F -box 蛋白 FBXO44 介导 BRCA1 的泛素化和降解。
J Biol Chem. 2012 Nov 30;287(49):41014-22. doi: 10.1074/jbc.M112.407106. Epub 2012 Oct 18.
7
Mechanisms of BRCA1 tumor suppression.BRCA1 肿瘤抑制作用的机制。
Cancer Discov. 2012 Aug;2(8):679-84. doi: 10.1158/2159-8290.CD-12-0221. Epub 2012 Jul 27.
8
Cysteine cathepsins: from structure, function and regulation to new frontiers.半胱氨酸组织蛋白酶:从结构、功能与调控到新前沿领域
Biochim Biophys Acta. 2012 Jan;1824(1):68-88. doi: 10.1016/j.bbapap.2011.10.002. Epub 2011 Oct 12.
9
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.BRCA1 肿瘤抑制作用是通过异染色质介导的沉默实现的。
Nature. 2011 Sep 7;477(7363):179-84. doi: 10.1038/nature10371.
10
HERC2 is an E3 ligase that targets BRCA1 for degradation.HERC2 是一种 E3 连接酶,可将 BRCA1 作为靶标进行降解。
Cancer Res. 2010 Aug 1;70(15):6384-92. doi: 10.1158/0008-5472.CAN-10-1304. Epub 2010 Jul 14.